Medable Inc., the leading technology provider for modern clinical trials, announced that its evidence generation platform was awarded “Best Digital Health Solution” from a field of 24 nominees at the Prix Galien USA Forum in New York City. Worldwide, the Prix Galien Award is regarded as the equivalent of the Nobel Prize for the life science industry. Winners from this year’s cohort include respected companies such as Bristol Myers Squibb, Eli Lily and Company, Novo Nordisk Inc., Boehringer Ingelheim and more.
Nine of the top 10 largest Contract Research Organizations (CROs) and 14 of the top 20 world’s largest pharmaceutical companies trust Medable’s platform and have deployed its technology in 300 clinical trials in 60 countries and 100+ local languages, touching the lives of more than one million patients and research participants globally. Medable’s customers have achieved impressive results with decentralized and hybrid trials – including 200 percent faster enrollment and 50 percent cost reductions.
“This recognition is a tremendous honor and validation of Medable’s unwavering commitment to ushering in a new era of drug development – one that merges technology and science to accelerate the development of new medicines,” said Medable CEO and co-founder Dr. Michelle Longmire. “Congratulations to all the nominees. We look forward to continuing to work with industry leaders and partners to accelerate the journey from scientific discovery to real-world impact, and further propel human health.”
Also Read: Trend Micro Achieves AWS Security Competency Status
The Prix Galien Awards are organized by the Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences. “Each year, the Awards Committee is astounded by the growing number of applicants and the level of passion, creativity and determination from the nominees who are developing their ideas into highly desirable solutions for patients around the world. We applaud their unwavering commitment to improving the human condition and are honored to celebrate their achievements,” said Bernard Poussot, Prix Galien Committee Chair (Categories: Medical Technology, Startups; Digital Health; and Incubators, Accelerators and Equity), Board Member, Roche Holding & Cargill Inc. Former Chairman & CEO, Wyeth.
Clinical research is burdened with antiquated processes that ultimately limit the number of new medicines that are able to reach patients in need. Medable’s software-as-a-service platform improves the speed, data capture, and accessibility of clinical trials across all therapeutic areas, thereby accelerating the development of new medicines. A 2022 financial modeling of decentralized clinical trials (DCTs) using industry benchmark and Medable data conducted by the Tufts Center for the Study of Drug Development shows that, on average, decentralized trials can achieve net financial benefits ranging from five to 13 times for Phase II and Phase III trials, due to reduced trial timelines and other factors.
SOURCE: Businesswire